Not all hormonal contraceptives are contraindicated for patients assigned female at birth undergoing testosterone therapy. The combined oral contraceptive pill, which contains oestrogen, should be avoided as it may interfere with the effects of testosterone therapy. However, the copper intrauterine device and progesterone-only pill are acceptable options as they do not have any adverse effects on testosterone therapy. The vaginal ring, which also contains oestrogen, should also be avoided.

Contraceptive and Sexual Health Guidance for Transgender and Non-Binary Individuals

The Faculty of Sexual & Reproductive Healthcare has released guidance on contraceptive choices and sexual health for transgender and non-binary individuals. The guidance emphasizes the importance of sensitive communication and offering options that consider personal preferences, co-morbidities, and current medications or therapies.

For individuals engaging in vaginal sex where there may be a risk of pregnancy and/or sexually transmitted infections, condoms and dental dams are recommended. Cervical screening and human papillomavirus vaccinations should also be offered to sexually active individuals with a uterus. Those engaging in anal sex and rimming should be advised of the risk of hepatitis A & B and offered vaccinations. Individuals at risk of HIV transmission should be advised of the availability of pre-exposure prophylaxis and post-exposure prophylaxis as required.

For patients seeking permanent contraception, a fallopian tube occlusion or a vasectomy may be the most appropriate solution and neither would be affected by hormonal therapy. Testosterone therapy does not provide protection against pregnancy, and oestrogen-containing regimes are not recommended in patients undergoing testosterone therapy. Progesterone-only contraceptives are considered safe, and the intrauterine system and injections may also suspend menstruation. Non-hormonal intrauterine devices do not interact with hormonal regimes but can exacerbate menstrual bleeding.

In patients assigned male at birth, there may be a reduction or cessation of sperm production with certain therapies, but the variability of effects means they cannot be relied upon as a method of contraception. Condoms should be recommended in those patients engaging in vaginal sex wishing to avoid the risk of pregnancy. Emergency contraception may be required in patients assigned female at birth following unprotected vaginal intercourse, and either of the available oral emergency contraceptive options may be considered. The non-hormonal intrauterine device may also be an option, but it may have unacceptable side effects in some patients.

Overall, the guidance stresses the importance of individualized care and communication in contraceptive and sexual health decisions for transgender and non-binary individuals.

Alfacalcidol as an Effective Treatment for CKD Patients

Alfacalcidol, also known as 1-hydroxycholecalciferol, is a form of vitamin D that is already hydroxylated and does not require activation by the kidney enzyme 1-hydroxylase. This makes it an effective alternative for patients with chronic kidney disease (CKD) as their impaired kidney function can compromise the bioavailability of other forms of vitamin D. Calcitriol is another option for CKD patients.

On the other hand, ascorbic acid, also known as vitamin C, is not involved in the modification of calcium metabolism but rather in the treatment of scurvy, a vitamin C deficiency. Cholecalciferol or vitamin D3, which is obtained from the diet or generated by UV action in the skin, must undergo hydroxylation in the kidney. Vitamin D2, on the other hand, requires activation by the kidney enzyme 1-hydroxylase, which can be impaired in CKD patients.

Lastly, riboflavin or vitamin B2 has no effect on calcium metabolism. In summary, alfacalcidol is an effective treatment option for CKD patients as it does not require activation by the kidney enzyme and can improve the bioavailability of vitamin D.

Evaluating Chest Pain after an MI

When a patient experiences chest pain within ten days of a previous myocardial infarction (MI), it is important to evaluate the situation carefully. Troponin T levels remain elevated for ten days following an MI, which can make it difficult to determine if a second episode of chest pain is related to the previous event. To make a diagnosis, doctors will need to evaluate the patient’s creatine kinase (CK)-myoglobin (MB) levels. These markers rise over three days and can help form a diagnostic profile that can help determine if the chest pain is related to a new MI or another condition. By carefully evaluating these markers, doctors can provide the best possible care for patients who are experiencing chest pain after an MI.

In cases of acute epiglottitis, protecting the airway is crucial and may require endotracheal intubation. Symptoms such as high fever, sore throat, dyspnoea, change in voice, and inspiratory stridor indicate a potential airway emergency. While other treatments may be necessary, securing the airway should be the top priority, following the ABCDE management steps. IV dexamethasone can help reduce laryngeal oedema, but an anaesthetic assessment should be arranged before administering any medication. Nebulised salbutamol is ineffective in treating laryngeal narrowing caused by epiglottitis. X-rays of the neck may be used, but they can take time to organise and delay urgent airway management. Attempting to visualise the larynx without appropriate senior support and intubation capabilities is dangerous in cases of acute epiglottitis. Flexible nasendoscopy should only be performed with the presence of trained personnel who can secure the airway if necessary.

Acute epiglottitis is a rare but serious infection caused by Haemophilus influenzae type B. It is important to recognize and treat it promptly as it can lead to airway obstruction. Although it was once considered a disease of childhood, it is now more common in adults in the UK due to the immunization program. The incidence of epiglottitis has decreased since the introduction of the Hib vaccine. Symptoms include a rapid onset, high temperature, stridor, drooling of saliva, and a tripod position where the patient leans forward and extends their neck to breathe easier. Diagnosis is made by direct visualization, but x-rays may be done to rule out a foreign body.

Immediate senior involvement is necessary, including those who can provide emergency airway support such as anaesthetics or ENT. Endotracheal intubation may be necessary to protect the airway. It is important not to examine the throat if epiglottitis is suspected due to the risk of acute airway obstruction. The diagnosis is made by direct visualization, but only senior staff who are able to intubate if necessary should perform this. Treatment includes oxygen and intravenous antibiotics.

The most specific test for diffuse cutaneous systemic sclerosis among patients is the presence of anti-Scl-70 antibodies.

Understanding Systemic Sclerosis

Systemic sclerosis is a condition that affects the skin and other connective tissues, but its cause is unknown. It is more common in females, with three patterns of the disease. Limited cutaneous systemic sclerosis is characterised by Raynaud’s as the first sign, affecting the face and distal limbs, and associated with anti-centromere antibodies. CREST syndrome is a subtype of limited systemic sclerosis that includes Calcinosis, Raynaud’s phenomenon, oEsophageal dysmotility, Sclerodactyly, and Telangiectasia. Diffuse cutaneous systemic sclerosis affects the trunk and proximal limbs, associated with scl-70 antibodies, and has a poor prognosis. Respiratory involvement is the most common cause of death, with interstitial lung disease and pulmonary arterial hypertension being the primary complications. Renal disease and hypertension are also possible complications, and patients with renal disease should be started on an ACE inhibitor. Scleroderma without internal organ involvement is characterised by tightening and fibrosis of the skin, manifesting as plaques or linear. Antibodies such as ANA, RF, anti-scl-70, and anti-centromere are associated with different types of systemic sclerosis.

Coronary Arteries and their Branches

The heart is supplied with blood by the coronary arteries. There are two main coronary arteries: the left and right coronary arteries. These arteries branch off into smaller arteries that supply different parts of the heart. Here are some of the main branches and their functions:

1. Circumflex artery: This artery supplies the left atrium.

2. Sinoatrial (SA) nodal artery: This artery supplies the SA node, which is responsible for initiating the heartbeat. In most people, it arises from the right coronary artery, but in some, it comes from the left circumflex artery.

3. Left anterior descending artery: This artery comes from the left coronary artery and supplies the interventricular septum and both ventricles.

4. Left marginal artery: This artery is a branch of the circumflex artery and supplies the left ventricle.

5. Posterior interventricular branch: This artery comes from the right coronary artery and supplies both ventricles and the interventricular septum.

Understanding the different branches of the coronary arteries is important for diagnosing and treating heart conditions.

Management Options for Urge Incontinence: Medications, Procedures, and Desmopressin

Urge incontinence is a common condition that can significantly impact a patient’s quality of life. While conservative treatments such as pelvic floor exercises and bladder training are often the first line of management, some patients may require additional interventions. Here are some options for managing urge incontinence:

Oxybutinin: This anticholinergic medication is often used as first-line treatment for urge incontinence that has not responded to conservative measures. It works by inhibiting muscarinic action on acetylcholine receptors, preventing muscle contraction. However, it is contraindicated in certain patients and can cause side effects such as dry mouth and constipation.

Percutaneous sacral nerve stimulation: This procedure involves a small stimulator that delivers stimulation to the sacral nerve, leading to contraction of the external sphincter and pelvic floor muscles. It is reserved for patients who have failed other treatments or cannot perform intermittent self-catheterization.

Augmentation cystoplasty: This surgical procedure is reserved for severe cases of urge incontinence that have not responded to other management options. It involves resecting a segment of the small bowel and suturing it to the bladder to increase its size. However, it is associated with numerous complications and requires follow-up.

Botulinum toxin: This is the first-line invasive management for patients who have not improved on anticholinergic medication or do not want drug therapy. It is injected into the bladder to inhibit the release of acetylcholine and provide symptom relief for up to six months.

Desmopressin: This synthetic analogue of antidiuretic hormone is used as second-line management for nocturia in patients with urge incontinence. It works by signaling the transportation of aquaporins in the collecting ducts of the kidney, leading to water reabsorption and less urine production. However, it is contraindicated in certain patients and can cause side effects such as hyponatremia and fluid retention.

In summary, there are several options for managing urge incontinence, ranging from medications to procedures. It is important to consider the patient’s individual needs and contraindications when selecting a treatment plan.

If a patient with SLE has an elevated CRP, it could indicate the presence of an infection. The patient in question does not have AKI and her kidney function is normal. Although she has a slight normocytic anemia, it is unlikely to be the cause of her symptoms. Fibromyalgia is common in SLE patients, but the elevated CRP in this case suggests an underlying infection rather than fibromyalgia. The patient’s elevated white blood cell count and CRP levels indicate the presence of an infection, rather than a lupus flare.

Systemic lupus erythematosus (SLE) can be investigated through various tests, including antibody tests. ANA testing is highly sensitive, making it useful for ruling out SLE, but it has low specificity. About 99% of SLE patients are ANA positive. Rheumatoid factor testing is positive in 20% of SLE patients. Anti-dsDNA testing is highly specific (>99%), but less sensitive (70%). Anti-Smith testing is also highly specific (>99%), but only 30% of SLE patients test positive. Other antibody tests include anti-U1 RNP, SS-A (anti-Ro), and SS-B (anti-La).

Monitoring of SLE can be done through various markers, including inflammatory markers such as ESR. During active disease, CRP levels may be normal, but a raised CRP may indicate an underlying infection. Complement levels (C3, C4) are low during active disease due to the formation of complexes that lead to the consumption of complement. Anti-dsDNA titres can also be used for disease monitoring, but it is important to note that they are not present in all SLE patients. Proper monitoring of SLE is crucial for effective management of the disease.

Differential Diagnosis for Cholestatic Jaundice in a Patient with UC

Primary sclerosing cholangitis (PSC) is a condition that should be considered in a patient with UC who presents with a raised alkaline phosphatase level. This is because approximately two-thirds of patients with PSC also have coexisting UC, and between 3% and 8% of UC sufferers will develop PSC. Chronic cholecystitis would present with pain, which is not present in this patient, making PSC the more likely diagnosis. Acute cholecystitis would present with right upper quadrant pain and obstructive liver function tests, which are not present in this case. Primary biliary cholangitis is more likely to affect women aged 30-60, and given the patient’s history of UC, PSC is more likely. Pancreatic carcinoma would be associated with weight loss and obstructive liver function tests. Therefore, in a patient with UC presenting with cholestatic jaundice, PSC should be considered as a possible diagnosis.

Perianal Manifestations in Inflammatory Bowel Disease: A Comparison

Inflammatory bowel disease (IBD) is a chronic condition that affects the digestive tract. Two main types of IBD are Crohn’s disease and ulcerative colitis. Both conditions can cause perianal manifestations, but the prevalence and severity differ.

Crohn’s disease is commonly complicated by perianal abscesses, fistula-in-ano, anal fissures, and skin tags. Up to 80% of patients with Crohn’s disease may suffer from perianal disease, which can significantly impair their quality of life. In contrast, perianal disease is far less common in patients with ulcerative colitis.

Coeliac disease, another digestive disorder, is not associated with perianal disease. However, it is linked to an increased risk of other autoimmune disorders such as type 1 diabetes and autoimmune thyroid disease.

Diverticular disease, which causes abdominal pain, bloating, constipation, and diarrhea, is also not associated with an increased risk of perianal disease.

Irritable bowel syndrome (IBS) is a functional disorder that causes symptoms such as bloating, cramping, abdominal pain, and constipation or diarrhea. Unlike IBD, IBS is not associated with an increased risk of perianal disease.

In summary, perianal manifestations are more commonly seen in Crohn’s disease than ulcerative colitis or other digestive disorders. A multidisciplinary approach may be required to manage severe cases of perianal Crohn’s disease.